|

FOLFIRI Clinical Trials

12 actively recruiting trials across 9 locations

▼ -1 trial since August 2026

Also known as: 5-fluorouracil, Arm B, Folinic acid, 5-FU, Irinatecan, folinic acid (leucovorin)

Pipeline

Phase 1: 6Phase 2: 2Phase 3: 2Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Incyte Corporation2
  • University of Alabama at Birmingham1
  • Oncolytics Biotech1
  • Janssen Research & Development, LLC1
  • Institut de Recherches Internationales Servier1

Indications

  • Cancer12
  • Unresectable Metastatic Colorectal Cancer2
  • Solid Tumors2
  • Colorectal Cancer2
  • Lung Cancer2

Birmingham, Alabama2 trials

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

University of Alabama at Birmingham

Phase 1

Tucson, Arizona2 trials

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

University of Arizona Cancer Center

Phase 1
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Local Institution - 0428

Phase 2/3

Other1 trial

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
Phase 3

Homewood, Alabama1 trial

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Central Alabama Research

Phase 2

Gilbert, Arizona1 trial

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Mayo Clinic Hospital

Phase 1

Los Angeles, California1 trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

The Angeles Clinic and Research Institute

Phase 1

Tampa, Florida1 trial

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Moffit Cancer Center

Phase 1

Savannah, Georgia1 trial

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

Low Country Cancer Care Associates_Savannah_1

Phase 3

Boston, Massachusetts1 trial

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.